Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab/relatlimab - Bristol-Myers Squibb

Next Previous
Drug Profile

Nivolumab/relatlimab - Bristol-Myers Squibb

Alternative Names: BMS-936558/BMS-986016; BMS-986213; Nivolumab and relatlimab-rmbw - Bristol-Myers Squibb; Nivolumab/relatlimab-rmbw - Bristol Myers Squibb; Opdualag; Relatlimab-rmbw/nivolumab - Bristol Myers Squibb; Relatlimab/nivolumab - Bristol Myers Squibb

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Phase I/II Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 24 Oct 2025 Bristol-Myers Squibb completes a phase-I/II clinical trials in Solid tumours (In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (NCT05134948)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (IV)
  • 30 May 2025 Efficacy and adverse event data from a phase III RELATIVITY-047 trial presented at the 61st Annual Meeting of the American Society of Clinical Oncology 2025 (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top